Bicuspidia aortica: epidemiologia, genetica e clinica

Q: What is the clinical evidence from this study?

Study design: Observational. Population: Severe aortic stenosis (n=87). Intervention: Medtronic Evolut R 34 mm valve vs. Medtronic Evolut R and PRO 26 mm and 29 mm valves. Primary outcome: VARC-2 composite device success failure (p=0.05).

Q: What does this research mean for the field?

Transcatheter aortic valve implantation (TAVI) with the Medtronic Evolut R 34 mm valve results in lower device success compared to smaller valve sizes, driven predominantly by paravalvular leaks. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Lamia Ait-Alì; Ilenia Foffa; Pierluigi Festa; Maria Grazia Andreassi

doi:10.1701/1206.13363

December 1, 2012Recenti Progressi in Medicina

Bicuspidia aortica: epidemiologia, genetica e clinica

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Bicuspid aortic valve is the most common congenital cardiac malformation with significant associated aortic pathology, but its pathogenesis and complications remain largely unknown.

Study Design

Type

Observational (n=87)

Multicenter

No

PICO

P

Population

87 adults with severe aortic stenosis underwent TAVI with Medtronic Evolut R or PRO valves in a single-center retrospective registry with up to 30-day follow-up.

E

Exposure / Comparator

Medtronic Evolut R 34 mm valve vs Medtronic Evolut R and PRO 26 mm and 29 mm valves

O

Primary Outcome

VARC-2 composite device success failure, p=0.05

Main Result

Absolute Event Rate: 21.42% vs 3.39%

p-value: p=0.05

Limitations

Retrospective study design
Single-center study
Relatively small population of patients in the group receiving the Evolut 34 valve
Newer valve models (Evolut 34+) designed to potentially diminish paravalvular leaks were not available during the study

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ait-Alì et al. (2012) conducted an observational in Severe aortic stenosis (n=87). Medtronic Evolut R 34 mm valve vs. Medtronic Evolut R and PRO 26 mm and 29 mm valves was evaluated on VARC-2 composite device success failure (p=0.05).

synapsesocial.com/papers/6ac5addb5235f006b2c4c457 https://doi.org/10.1701/1206.13363